Hemophilia primarily affects males, with an estimated prevalence of 1 in 5,000 males worldwide and an incidence of about 1 in 1,333 live male births. The condition occurs across all racial, ethnic, and geographic groups, though the experience of living with hemophilia varies significantly depending on severity, sex, ethnicity, and access to specialized care.
Why Males Are Almost Always Affected
Hemophilia is caused by mutations in genes that produce clotting factors, and those genes sit on the X chromosome. Males have only one X chromosome (paired with a Y chromosome, which carries no clotting factor genes). If a male inherits an X chromosome with a hemophilia mutation, he has no backup copy to compensate, so he will have the disorder.
Females have two X chromosomes. If one carries a hemophilia mutation, the other typically produces enough clotting factor to prevent serious bleeding. This is why hemophilia can remain hidden in a family for generations, passed silently through female carriers without anyone showing symptoms. Over half of new hemophilia diagnoses have no prior family history of the condition.
Females With Hemophilia
The old assumption that women can only be “carriers” is outdated. Some women who inherit a single hemophilia gene do develop low clotting factor levels and experience real bleeding symptoms. These symptoms are usually milder than those seen in males, but in rare cases they can be just as severe. This happens when the normal X chromosome doesn’t function properly, or in the uncommon situation where a woman inherits a hemophilia gene from both parents.
Unfortunately, the misconception that hemophilia is exclusively a male condition means some women with bleeding symptoms are never tested. Their diagnosis and treatment can be delayed for years. Any woman with a family history of hemophilia and unexplained bleeding, heavy menstrual periods, or prolonged bleeding after dental work or surgery should be evaluated for low clotting factor levels.
Hemophilia A vs. Hemophilia B
Both types follow the same inheritance pattern and affect the same general population. Hemophilia A, which involves a deficiency in clotting factor VIII, is the more common form, accounting for roughly 80% of cases. Hemophilia B involves a deficiency in clotting factor IX and makes up the remaining 20%. Severity ranges from mild to severe depending on how much functional clotting factor a person produces, and that severity level shapes nearly every aspect of the condition, from when it’s diagnosed to how it’s managed day to day.
Age at Diagnosis by Severity
Severe hemophilia is typically identified early. According to CDC data, the median age at diagnosis for severe hemophilia is about 1 month, often because newborns develop unusual bruising or prolonged bleeding after circumcision or a heel prick test. Moderate hemophilia is usually caught around 8 months, when a baby starts crawling and bumping into things. Mild hemophilia often goes undetected until around 36 months, or even later, because bleeding episodes are less frequent and may only surface after a significant injury or surgical procedure.
A large French cohort study found a similar pattern, with severe cases diagnosed at a median of 5.8 months and mild cases not identified until a median of 28.6 months. When a family already has a child with hemophilia, younger siblings tend to be tested and diagnosed almost immediately, at a median of about two weeks after birth.
Racial and Ethnic Differences
Hemophilia itself does not favor one racial or ethnic group over another. Data from specialized treatment centers in the United States show roughly similar prevalence rates: about 15.1 per 100,000 males among White populations and 12.4 per 100,000 among Black and Hispanic populations. That small gap likely reflects differences in access to diagnosis and specialty care rather than a true biological difference in how often the condition occurs.
Where race does matter is in complications and outcomes. Black and Hispanic people with hemophilia consistently face a higher risk of developing inhibitors, which are antibodies that attack replacement clotting factor and make standard treatment ineffective. In severe hemophilia A, inhibitors develop in nearly 30% of patients who are newly treated, but the risk is disproportionately higher in Black and Hispanic patients. Black people with hemophilia also tend to have worse physical functioning scores, pointing to broader disparities in the quality and consistency of care they receive.
Who Develops Inhibitors
Inhibitors represent the most serious complication of hemophilia treatment and affect a specific subset of the population more than others. The biggest predictor is genetic: certain types of mutations in the clotting factor gene, particularly those that completely prevent the body from producing any clotting factor at all, carry the highest inhibitor risk. People with severe hemophilia are far more likely to develop inhibitors than those with moderate or mild forms.
Environmental factors also play a role. Early age at first treatment, high-intensity treatment (such as receiving large amounts of clotting factor after surgery or a major bleed), and concurrent infections or vaccinations at the time of treatment have all been linked to increased inhibitor risk. This means young children undergoing their first treatments during a medical emergency are among the most vulnerable.
Global Gaps in Diagnosis
The 1-in-5,000 prevalence figure is an estimate, and the true global number of people living with hemophilia is almost certainly higher than what registries capture. In high-income countries with established screening programs, most cases are identified in infancy or early childhood. In low- and middle-income countries, many people with hemophilia are never diagnosed at all, or are diagnosed only after life-threatening bleeding events. The World Federation of Hemophilia has been building a global registry to close this gap, but underdiagnosis remains a significant problem in regions without access to specialized coagulation labs and treatment centers.
Even within well-resourced countries, mild hemophilia is frequently missed. Because people with mild hemophilia produce enough clotting factor to handle everyday bumps and cuts, they may not bleed abnormally until they face a major surgery or trauma. Some aren’t diagnosed until adulthood.